Once the Walter Reed results come out in the period ahead just at the same time as phase 1 and the company gets an additional 5-10 million dollars of non dilutive funding from the US defence department and its subsidiaries it’s exciting times ahead. Even though it’s a laughable that a biotech that actually works with currently 5.6 million in the bank with around 4 million coming in R&D rebates is valued at a 10 million market cap. GLP results shortly then straight into Walter Reed and phase 1 for both TB and stroke
AML received a 1.1 million dollar order of a product from the US Navy and it’s a 100 million market cap now. Once NYR come out with its results with the US department of defence which is already heavily de risked exciting times
NYR Price at posting:
6.3¢ Sentiment: Buy Disclosure: Held
